Skip to main content
ARIX BIOSCIENCE PLC logo

ARIX BIOSCIENCE PLC — Investor Relations & Filings

Ticker · ARIX ISIN · GB00BD045071 LEI · 213800OVT3AHQCXNIX43 IL Financial and insurance activities
Open in API
Filings indexed 547 across all filing types
Latest filing 2020-02-27 Report Publication Anno…
Country GB United Kingdom
Listing IL ARIX

About ARIX BIOSCIENCE PLC

https://www.arixbioscience.com/

Arix Bioscience plc is a global venture capital company that specializes in the biotechnology and life sciences sectors. The firm's primary activity involves investing in and building innovative biotech companies, providing capital and strategic support from early stages, including seed, preclinical, and clinical development. Arix focuses on identifying and nurturing breakthrough advances in life sciences to accelerate the development of new medical technologies and therapies. According to public information, the company has entered into a process of liquidation.

Recent filings

Filing Released Lang Actions
Arix Bioscience Plc - Notice of Results
Report Publication Announcement Classification · 1% confidence The document is titled "Arix Bioscience Plc - Notice of Results" and explicitly states that the company "will announce its annual results for the year ended 31 December 2019, on Tuesday 10 March 2020." It also mentions a subsequent analyst presentation and webcast. Since the document is a short notice *announcing* the future release of results rather than containing the full results or the management discussion/analysis itself, it fits the definition of a Report Publication Announcement (RPA). The document length (1980 chars) is very short, supporting the 'MENU VS MEAL' rule.
2020-02-27 English
Arix Bioscience Plc - Aura announces updated Phase 1b/2 clinical data
Regulatory Filings Classification · 1% confidence The document is a press release issued by Arix Bioscience plc, noting that its portfolio company, Aura Biosciences, presented updated clinical data from a Phase 1b/2 trial at a medical meeting (43rd Annual Macula Society Meeting). The text details clinical findings (safety, efficacy, tumor control) and discusses the planned Phase 3 trial. This content is characteristic of an announcement regarding clinical trial progress, which is typically disseminated via an Earnings Release (ER) if it coincides with financial reporting, or more generally as a Regulatory Filing (RNS) or Investor Presentation (IP) if it's a standalone update. Since it is a press release announcing clinical data updates, and not a formal comprehensive report (like 10-K or IR), nor a formal presentation document (IP), the most appropriate classification is Earnings Release (ER) as these updates often accompany or substitute for formal earnings commentary, or RNS as a general regulatory announcement. Given the focus is purely on clinical data presentation and not financial results highlights, RNS is a strong candidate. However, in many databases, significant clinical updates released via PR Newswire are often categorized under ER if they are timely, or RNS if they are purely informational. Since this is a detailed update on a product candidate's trial status, and it is being disseminated via a press release format, it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to a specific reporting period's results. Given the lack of explicit financial results summary, RNS is the safer, broader category for non-standard regulatory announcements. I will lean towards RNS as the most accurate fallback for a clinical data press release not explicitly labeled as an ER or IP.
2020-02-24 English
Hardman & Co Research: Arix Bioscience (ARIX) - Initiation of coverage: With high risk can come high reward
Report Publication Announcement Classification · 1% confidence The document is a short announcement (3959 characters) from 'Hardman & Co Research' regarding Arix Bioscience. It summarizes key points (NAV, portfolio size) and explicitly states, 'Please click on the link below for the full report:'. This structure—a brief summary pointing to a full, external document—is characteristic of a Report Publication Announcement (RPA), rather than the full research report itself (which would likely be classified as IP or potentially AR/FS if it were a standard company document). Since it is an announcement about the publication of research, RPA is the most appropriate classification based on Rule 2.
2020-02-19 English
Arix Bioscience Plc - Imara files for proposed IPO in the United States
Capital/Financing Update Classification · 1% confidence The document is a press release from Arix Bioscience plc announcing that its portfolio company, Imara Inc., has filed a registration statement on Form S-1 with the SEC for a proposed Initial Public Offering (IPO) in the United States. The key elements are the announcement of a financing/fundraising activity (IPO filing) and the mention of specific regulatory forms (Form S-1, SEC filing). This directly aligns with the definition of 'Capital/Financing Update' (CAP). Although it mentions an SEC filing, the core subject is the capital raising event, not a general regulatory announcement (RNS) or a comprehensive report (10-K/IR).
2020-02-17 English
Arix Bioscience Plc - Autolus presents encouraging additional AUTO3 data
Regulatory Filings Classification · 1% confidence The document is a press release issued by Arix Bioscience plc, reporting on an announcement made by its portfolio company, Autolus Therapeutics plc, regarding clinical trial data for a therapy (AUTO3) presented at a medical meeting (EHA-EBMT 2nd European CAR T Cell Meeting). This type of announcement, detailing clinical progress, financial highlights, and strategic updates via a press release format, is characteristic of an Earnings Release (ER) or a general Investor Presentation (IP) if it were a slide deck. However, since it is a news release announcing data presentation and includes forward-looking statements and contact information typical of immediate market updates, it aligns best with an Earnings Release (ER) which often covers key operational/clinical milestones outside of formal quarterly reporting periods, or potentially an Investor Presentation (IP) if the content were structured as slides. Given the structure (PR Newswire header, date, summary of data, contact info, and boilerplate about the company), it functions as an immediate release of material information. Since it is not a full quarterly report (IR) or a formal presentation deck (IP), and it contains key results, 'ER' is the most appropriate fit for a material, non-statutory announcement of results/progress. It is not a Report Publication Announcement (RPA) because it contains the substantive information, not just a notice that a report is available.
2020-01-30 English
Arix Bioscience Plc - Arix co-founds Quench Bio with Series A financing
Capital/Financing Update Classification · 1% confidence The document is a press release announcing that Arix Bioscience's portfolio company, Quench Bio, has emerged from stealth mode following a Series A financing round, bringing total funding to $50 million. This announcement details financing activities, the company's scientific focus (Gasdermin D inhibition), and key personnel/investor changes. This content directly relates to fundraising and capital structure changes for a portfolio company, which aligns best with the 'Capital/Financing Update' category (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it is a specific corporate finance event announcement.
2020-01-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.